Gardasil's FDA Approval Now Includes Some Vaginal And Vulvar Cancers The US Food and Drug Administration (FDA) has approved Merck's cervical vaccine Gardasil for protecting against vaginal and vulvar cancers caused by Human Papillomavirus (HPV) types 16 and 18 in girls and women aged from 9 to 26. The agency announced its decision to the press on Friday 12th September, in a FDA News page on its website.
Source: www.medicalnewstoday.comPhysical Therapy As Effective As Arthroscopic Knee Surgery, New Research Finds A new study questioning the usefulness of arthroscopic surgery for osteoarthritis of the knee should encourage patients to consider physical therapy as an effective non-surgical option, according to the American Physical Therapy Association (APTA). The study was published in the New England Journal of
Medicine (NEJM).
Source: www.medicalnewstoday.comNew Tutorial Discusses Health Care, Long-Term Care For Older Women; GAO Report Examines Health Centers In Medically Underserved Areas "
Health Care and Long-Term Care Policy: Concerns Facing Older Women," kaiserEDU.org: The slide tutorial -- narrated by Alina Salganicoff, vice president and director of women's
health policy at the
Source: www.medicalnewstoday.comBlogs Comment On Palin, Feminists For Life, Presidential Election Rhetoric, Protecting Patients' Rights The following is a summary of selected women's
health-related blog entries.~ "Feminists for Life's Imaginary World," Amanda Marcotte, RH Reality Check: "In order to back the claim that she's 'pro-woman'" Republican vice presidential nominee and Alaska Gov. Sarah Palin claims affiliation with the antiabortion organization
Source: www.medicalnewstoday.comGenital Cutting Prevalence In Ethiopia Decreasing, Survey Finds The prevalence of female genital cutting -- also referred to as female genital mutilation and female circumcision -- has decreased in Ethiopia from 61% of girls and women in 1997 to 46% in 2007, according to a 2007 survey by the Ethiopian National Committee on Traditional Practices, or EGLDAM, IRIN News reports.
Source: www.medicalnewstoday.comCross-Protective Efficacy And Prevention Of Precancerous Vaginal Lesions Added To Gardasil(R) I Product Information The product information of the four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® has been updated to include cross-protective efficacy in preventing precancerous cervical lesions (CIN2/3 and AISiii) due to additional cancercausing HPV types related to HPV type 16.1 Statistically significant efficacy against disease was demonstrated against HPV 31 which is the second most common HPV type in Europe in causing precancerous cervical lesions, after type 16.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 PM
